APi Group (APG) Company Overview

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) has announced that it plans to share its financial results for the last three months and the entire year ending December 31, 2024, before the market opens on Wednesday, February 26, 2025. They will also host a conference call to discuss these results at 8:30 a.m. (Eastern Time) on the same day, with Russell A. Becker participating in the call.

Enrollment for Part A of the trial finished earlier than expected and exceeded the goal with 123 patients signed up. The 16-week proof-of-concept results for Part A are expected in mid-2025. Additionally, the first patient has been treated in Part B of the Phase 2 APEX clinical trial for APG777, which targets moderate-to-severe atopic dermatitis.

ATLANTA--(BUSINESS WIRE)--Oldcastle® APG, part of CRH, has introduced Catalyst™ Fence Solutions, which is its main brand for fencing products.

I maintain a buy rating for APG because of its strong potential for market share, growth acceleration, and expected increase in adjusted EBITDA margins for FY25 and later. The company shows solid demand with a $3.5 billion backlog, strong end markets, and a promising pipeline for mergers and acquisitions, which supports high-single-digit growth. Although there has been a revision in revenue guidance for FY24 due to temporary project delays, this positions FY25 for stronger growth with encouraging trends in proposal activity.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) has announced that it will hold an Investor Day on Wednesday, May 21, 2025, in New York City. More information about the venue, attendees, and how to watch the event online will be provided in the upcoming months. Russ Becker, the President and CEO of APi, expressed gratitude to the company's leaders for their efforts as they approach the end of 2024, highlighting record net revenues.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) has announced that Kevin Krumm, the Chief Financial Officer, will leave his position on December 13, 2024, to pursue a new opportunity. David Jackola, who is currently the Chief Financial Officer and Vice President of Transformation at APi International, will take over as interim Chief Financial Officer until a new permanent CFO is found. Jackola brings extensive experience in senior finance roles.

Apogee Therapeutics' APG777 appears to be a promising treatment for atopic dermatitis, requiring less frequent doses and possibly helping with asthma, COPD, and psoriasis. The company's research pipeline also features APG808 and APG990, which focus on various inflammatory pathways, increasing its potential in the inflammation and immunology market. With a solid financial position and several important upcoming events, such as Phase 2 results for APG777, the company's current high valuation is supported.

APi Group Corporation (NYSE:APG) will hold its Q3 2024 Earnings Conference Call on October 31, 2024, at 8:30 AM ET. The call will feature company representatives, including Adam Fee, Russell Becker, and Kevin Krumm, along with analysts from various firms. Participants are currently in listen-only mode until the Q&A session begins.

APi (APG) reported quarterly earnings of $0.51 per share, matching the Zacks Consensus Estimate. This is an increase from earnings of $0.48 per share from the same period last year.